Welcome to our dedicated page for TC BioPharm (Holdings) news (Ticker: TCBP), a resource for investors and traders seeking the latest updates and insights on TC BioPharm (Holdings) stock.
TC BioPharm (Holdings) plc develops clinical-stage allogeneic gamma-delta T-cell therapies for cancer and other indications through its American depositary shares. Company news centers on TCB008, its unmodified gamma-delta T-cell product line, and ACHIEVE clinical-trial updates in acute myeloid leukemia, myelodysplastic syndromes/AML, relapse or refractory disease, and minimal residual disease.
Recurring updates also cover use of the company's CryoTC technology for frozen cell-therapy supply, safety and response observations from dosing cohorts, operating changes tied to outsourced production and decentralized drug development, and public-company matters such as ADS trading status and OTC market transition.
TC BioPharm (NASDAQ: TCBP) announced the execution of a non-binding letter of intent to acquire a biotechnology company focusing on CAR-T therapies for refractory cancers and solid tumors. The acquisition target has proven the therapeutic potential of its lead CAR-T candidate for various solid tumors and is also developing a novel allogeneic CAR-T for autoimmune diseases. The potential acquisition aims to expand TC BioPharm's therapeutic platform and bring synergies in CAR development expertise, providing multiple shots on goal for the treatment of various indications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.